NEW YORK (GenomeWeb News) – Natural products firm ChromaDex and the Scripps Center for Metabolomics have formed a partnership to generate tandem mass spectrometry data for compounds for inclusion in a metabolite database
Data from compounds from ChromaDex's products and phytochemical catalog will be included in the Scripps Metlin Metabolite Database, which contains metabolite information, such as tandem mass spectrometry information, for more than 55,000 potentially therapeutic compounds.
Metlin, however, has only limited data on natural products, and including such information would enable researchers to screen potential compounds for use in areas of clinical interest, such as cancer, heart disease, diabetes, and Alzheimer's disease, ChromaDex said.
The collaboration announced today "will further advance small molecule profiling to increase demand for natural product libraries through the ease of the Internet to assist in finding candidate compounds for research and development," ChromaDex Founder and Chief Scientific Officer Frank Jaksch said in a statement.
ChromaDex is based in Irvine, Calif., and provides solutions and ingredients to the dietary supplement, food and beverage, cosmetic, and pharmaceutical industries.
Gary Siuzdak, senior director for the Center for Metabolomics and Mass Spectrometry Scripps Research Institute, added that the inclusion of ChromaDex compounds "will expand Metlin's compound library and mass spectrometry data to nutraceuticals and many novel plant-related natural products. The importance in the ChromaDex/Metlin partnership is that it will facilitate metabolomics experiments around the world."
Financial and other terms of the deal were not disclosed.